RHÖN-KLINIKUM AG: Intended increase of Asklepios' shareholding in RHÖN-KLINIKUM AG to 10.1% of all shares prohibited by Federal Cartel Office

RHÖN-KLINIKUM AG  / Key word(s): Miscellaneous

30.07.2013 12:15

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.



Ad hoc-Notification pursuant to Section 15 (1) WpHG

Intended increase of Asklepios' shareholding in RHÖN-KLINIKUM AG to 10.1%
of all shares prohibited by Federal Cartel Office

By resolution dated 12 March 2013, the German Federal Cartel Office
(Bundeskartellamt) had approved the increase of Asklepios
Verwaltungsgesellschaft mbH's ('Asklepios') shareholding in RHÖN-KLINIKUM
AG to 10.1% subject to, amongst other conditions, the condition precedent
of Asklepios selling the Harz clinic (Dr. Herbert-Nieper-Krankenhaus) and
the medical service center (MVZ Harz) operated by Asklepios in the Goslar
area to an independent hospital operator. For that purpose, Asklepios was
also obligated under the resolution of the Federal Cartel Office to appoint
a hold separate manager and a security trustee (Sicherungstreuhänder).

On 29 July 2013, the Federal Cartel Office informed the Company that
Asklepios will not fulfil the condition precedent. The mandates of the hold
separate manager and the security trustee, which had been issued in the
meantime, have been terminated by Asklepios. Hence, the conditions
precedent can no longer be fulfilled. The Federal Cartel Office has
declared that the intended increase of Asklepios' shareholding to 10.1% is
now prohibited in accordance with the resolution of 12 March 2013.

Due to the prohibition, the decision of the Federal Cartel Office of 12
March 2013 challenged by RHÖN-KLINIKUM AG before the Higher Regional Court
of Düsseldorf is obsolete (erledigt) in a legal sense. RHÖN-KLINIKUM AG
intends, however, to continue the clarification of the legal situation
pursued with the appeal procedure by way of a continued appeal
(Fortsetzungsfeststellungsbeschwerde). Thereby the Company intends, in view
of a possible renewed filing for merger control clearance of the
acquisition of a blocking minority by Asklepios, to have determined by the
court that the merger control clearance of such acquisition is
impermissible for a variety of reasons that, from the Company's point of
view, were not taken into consideration in the Federal Cartel Office's
decision of 12 March 2013.

Contact:

RHÖN-KLINIKUM AG

Dr. Kai G. Klinger
Head of Investor Relations
Schlossplatz 1
97616 Bad Neustadt a. d. Saale
Tel: +49 (0) 9771 65-1318
Fax: +49 (0) 9771 99-1736
E-Mail: kai.klinger@rhoen-klinikum-ag.com

Sascha Schiffler
Head of Group Press and Public Relations
Schlossplatz 1
97616 Bad Neustadt a. d. Saale
Tel: +49 (0) 9771 65-1327
Fax: +49 (0) 9771 65-1820
E-Mail: kommunikation@rhoen-klinikum-ag.com


30.07.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


 
Language:     English
Company:      RHÖN-KLINIKUM AG
              Schlossplatz 1
              97616 Bad Neustadt a.d.Saale
              Germany
Phone:        +49 (0)9771 - 65-0
Fax:          +49 (0)9771 - 97 467
E-mail:       rka@rhoen-klinikum-ag.com
Internet:     www.rhoen-klinikum-ag.com
ISIN:         DE0007042301
WKN:          704230
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), München;
              Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
 
End of Announcement                             DGAP News-Service